27 Micronutrients, 884 Trials: What Prevents Heart Disease?

The supplement aisle promises a crowded cardiovascular defense team. The largest evidence map in cardiology found a much shorter roster: among 27 micronutrients tested in 884 randomized trials, only omega-3 fatty acids, folic acid, and coenzyme Q10 showed statistically significant effects on selected hard cardiovascular outcomes. Beta-carotene showed replicated harm in people exposed to cigarette smoke. The other 24 nutrients did not produce convincing reductions in heart attacks, strokes, cardiovascular death, or all-cause mortality.

That does not mean nutrients do nothing. Many supplements change blood levels, lipids, blood pressure, or glucose markers. But preventing an event is a higher bar than improving a lab value. The distinction matters when the event is a myocardial infarction rather than a more flattering vitamin D result on a dashboard.

What the 884-trial scorecard actually measured

The 2022 JACC review by An et al. synthesized 884 randomized controlled trials involving 883,627 participants and 4.9 million person-years of follow-up. It assessed 27 micronutrients and separated changes in cardiovascular risk factors from clinical outcomes. That design makes it useful for a basic question: does swallowing an isolated nutrient prevent cardiovascular events?

Most often, the answer was no convincing evidence of benefit on hard endpoints. The review found moderate- to high-quality evidence that several products can improve risk factors, including vitamin D, magnesium, zinc, CoQ10, and omega-3 fatty acids. Yet risk-factor movement did not reliably translate into fewer heart attacks, strokes, or deaths.

The review's three favorable signals need context. Omega-3 fatty acids reduced coronary heart disease mortality in pooled trials (relative risk [RR] 0.85, 95% confidence interval [CI] 0.77–0.94) and nonfatal coronary heart disease events (RR 0.87, 95% CI 0.82–0.93). Folic acid reduced stroke in pooled data (RR 0.80, 95% CI 0.71–0.90). CoQ10 was associated with lower all-cause mortality (RR 0.68, 95% CI 0.49–0.94), though that estimate comes from a very different population than a healthy person shopping for longevity supplements.

Omega-3: a pooled signal with two large primary-prevention null trials

Omega-3 is the least dismissible supplement on this list, but its primary-prevention story is unresolved. Across the trials pooled in the JACC review, the estimates for coronary heart disease death and nonfatal coronary events were statistically significant. Pooled evidence, however, combines studies with different populations, formulations, doses, and background diets. The largest individual trials at a commonly marketed dose did not meet their primary endpoints.

In VITAL, 25,871 participants received 1 g per day of omega-3 fatty acids or placebo and were followed for 5.3 years. The prespecified major adverse cardiovascular event composite was not significantly lower with omega-3: hazard ratio (HR) 0.92, 95% CI 0.80–1.06; p=0.24. ASCEND tested 1 g per day in 15,480 people with diabetes and likewise found no significant reduction in its primary major adverse cardiovascular event endpoint (RR 0.97, 95% CI 0.87–1.08; p=0.55).

VITAL did report fewer total myocardial infarctions as a secondary endpoint (HR 0.72; p=0.003). That result is worth knowing, but it cannot replace the null prespecified primary composite. Secondary outcomes can generate useful hypotheses; they do not automatically settle the primary question.

Higher-dose prescription-style EPA has not made interpretation simpler. REDUCE-IT used 4 g per day of EPA ethyl ester and reported a 25% reduction in major adverse cardiovascular events, but its mineral-oil placebo may have raised LDL cholesterol and C-reactive protein in the control group. STRENGTH, which used the same dose with a corn-oil placebo, was null (HR 0.99). These trials differed in more than placebo choice, so they cannot prove that placebo alone explains their disagreement. They do show why a single impressive result should not become a universal supplement recommendation.

Folic acid works where folate status leaves room to work

The pooled folic-acid stroke result is largely driven by the China Stroke Primary Prevention Trial. That trial enrolled 20,702 Chinese adults with hypertension in a setting without mandatory flour fortification. Folic acid was associated with lower stroke risk: HR 0.79, 95% CI 0.68–0.93; p=0.003.

This is a strong result for that population, not a blank check for people who already get folic acid from fortified grain products. Western trials in fortified settings, including HOPE-2, NORVIT, and VISP, showed attenuated or null stroke effects. In the United States, Canada, the United Kingdom, and Australia, mandatory flour fortification has raised baseline folate status. For most healthy adults there, extra folic acid has no demonstrated stroke-prevention role. Pregnancy and documented folate deficiency remain separate clinical questions.

CoQ10's mortality result belongs to heart-failure care, not primary prevention

CoQ10 produced the largest mortality estimate in the JACC map, but the underlying evidence does not apply to healthy adults. Q-SYMBIO enrolled 420 patients with New York Heart Association class III–IV heart failure and compared 300 mg per day of CoQ10 with placebo. All-cause mortality over two years was 9% with CoQ10 and 17% with placebo (HR 0.57, 95% CI 0.35–0.93). In that specific trial, the approximate number needed to treat was 12 over two years.

Those numbers deserve follow-up, not extrapolation. Q-SYMBIO was conducted before sacubitril/valsartan and SGLT2 inhibitors became standard treatments for heart failure with reduced ejection fraction. Its placebo mortality rate may not reflect modern care, the trial received co-funding from manufacturer Pharma Nord, and no adequately powered independent replication exists. CoQ10 has no credible evidence base for cardiovascular primary prevention in healthy people.

Beta-carotene has a warning label written by randomized trials

High-dose beta-carotene is the clearest supplement hazard in this evidence map for smokers and people with substantial smoke exposure. In ATBC, 29,133 male smokers took 20 mg per day. Beta-carotene increased all-cause mortality (RR 1.08, 95% CI 1.01–1.16) and lung-cancer incidence (RR 1.18, 95% CI 1.03–1.36).

CARET reinforced the concern. The trial enrolled 18,314 smokers and asbestos-exposed workers and tested 30 mg per day of beta-carotene plus retinol. All-cause mortality increased (RR 1.17, 95% CI 1.03–1.33), and investigators stopped the trial early. In the Physicians' Health Study of nonsmokers, beta-carotene's RR was about 1.00. The pattern points to smoke exposure as the relevant risk modifier. The proposed pro-oxidant mechanism under high oxidative stress fits the trial results, but the clinical finding is enough: smokers and former smokers should avoid high-dose beta-carotene supplements.

Vitamin D illustrates the biomarker problem

Vitamin D is widely marketed for cardiovascular health, yet VITAL found no reduction in its prespecified cardiovascular outcomes with 2,000 IU per day. Among 25,871 participants followed for 5.3 years, the HR for major adverse cardiovascular events was 0.97 (95% CI 0.85–1.12; p=0.69). Myocardial infarction (HR 0.96, 95% CI 0.78–1.18) and stroke (HR 0.95, 95% CI 0.76–1.20) were also null.

A 2024 meta-analysis in people with type 2 diabetes found vitamin D improved HbA1c, fasting blood sugar, lipids, and blood pressure markers. Those are surrogate outcomes. They do not overturn the absence of demonstrated hard-event benefit in the large trial evidence.

Food patterns have a better case than isolated pills

The alternative is not nutritional nihilism. Dietary patterns can alter many exposures at once: fiber, fats, potassium, protein sources, food processing, and overall calorie intake. A 2024 network meta-analysis of randomized dietary interventions found consistent evidence that Mediterranean-style patterns reduce cardiovascular morbidity and mortality. In overweight and obese adults, a 2025 systematic review of 26 randomized trials reported that the revised PREDIMED trial associated a Mediterranean diet with a 35% lower risk of myocardial infarction, stroke, or cardiovascular death.

The evidence in women also points in the same direction, though it includes both randomized trials and prospective cohorts. A 2023 systematic review and meta-analysis examined Mediterranean-diet adherence and primary cardiovascular prevention in women. It supports the diet pattern as a reasonable prevention strategy, while its observational components cannot prove that diet alone caused the lower event rates.

The practical verdict

Correct a documented deficiency. Use folic acid when pregnancy guidance calls for it. Avoid high-dose beta-carotene if you smoke or used to smoke. Beyond that, do not expect vitamin D, vitamin E, vitamin C, selenium, zinc, vitamins B6 or B12, vitamin A, vitamin K, or most other isolated micronutrients to prevent cardiovascular events in a generally healthy, nutrient-replete adult.

Omega-3 at 1 g per day has a favorable pooled signal but null primary endpoints in the two largest trials, so modest benefit is the most defensible expectation for primary prevention. CoQ10's heart-failure result is interesting but does not justify preventive use in healthy people. Put the larger share of effort into a dietary pattern with clinical-outcome evidence; the supplement stack has not earned equal billing.